Recursion Pharmaceuticals stock falls due to weaker-than-expected first-quarter results, along with the abandonment of ...

Tempus AI reports first-quarter revenue of $255.74 million, beating estimates of $248.13 million. The AI-focused precision ...

Tempus AI shares rose after a Q1 beat, as an analyst highlighted its AI-driven growth, expanding pharma deals, and $1B+ ...

Please go ahead. Thank you. Good afternoon and welcome to Tempus' first quarter 2025 conference call. This afternoon, Tempus released results for the quarter ended March 31, 2025. The press ...

Tempus enters earnings with strong tailwinds but elevated scrutiny. The stock has surged over 80% in the past six months, and analysts have maintained tight but bullish targets — averaging $61. ...

CEO Eric Lefkofsky highlighted a record quarter for Tempus, with quarterly revenue increasing 75.4% year-over-year to $255.7 million. Genomics revenue grew 89% year-over-year to $193.8 million ...

CHICAGO (AP) — CHICAGO (AP) — Tempus AI Inc. (TEM) on Tuesday reported a loss of $68 million in its first quarter. On a per-share basis, the Chicago-based company said it had a loss of 40 cents.

Please go ahead. Thank you. Good afternoon. And welcome to Tempus’ first quarter 2025 conference call. This afternoon, Tempus released results for the quarter ended March 31, 2025. The press ...

Tempus AI continued to see dramatic revenue and gross profit growth in the first quarter, with year-over-year revenue up 75.4% and quarterly gross profit nearly doubling, the Chicago-based health ...

High-rolling investors have positioned themselves bearish on Tempus AI (NASDAQ:TEM), and it's important for retail traders to take note. \This activity came to our attention today through Benzinga ...

Tempus AI Inc. (TEM) reported its first-quarter 2025 earnings, showcasing a robust revenue increase of 75.4% year-over-year, reaching $255.7 million, surpassing the forecast of $248.5 million.